Rigel Pharmaceuticals Q4 Earnings Outlook

On Tuesday, Rigel Pharmaceuticals RIGL will release its latest earnings report. Benzinga's outlook for Rigel is included in the following report.

Earnings and Revenue

Rigel Pharmaceuticals EPS is expected to be at a loss of 13 cents, according to sell-side analysts. Sales will likely be near $40,000.

In the same quarter last year, Rigel Pharmaceuticals reported an EPS loss of 16 cents on revenue of $3 million. If the company were to match the consensus estimate when it reports Tuesday, earnings would be up 18.75 percent. Revenue would be down 98.67 percent from the same quarter last year.

Here's how the Rigel Pharmaceuticals's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

For a full 12 months, the return has risen by 37.86 percent. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts have been rating Rigel Pharmaceuticals stock as Neutral. The strength of this rating has maintained conviction over the past three months.

Conference Call

Rigel's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.